# Zhengye Biotechnology Holding Ltd > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Zhengye Biotechnology Holding Ltd). ## Overview Zhengye Biotechnology Holding Ltd is a Cayman Islands holding company with operating activities centered in Jilin, China through its veterinary vaccine business. The company develops, manufactures, and sells veterinary vaccines, with a particular focus on livestock vaccines in China. ## Products & services • Veterinary vaccine research and development • Manufacturing of livestock vaccines • Sales of veterinary vaccines • Animal health biologics for farm use - **Veterinary vaccines** (85%) — Vaccines designed to prevent disease in livestock and other farm animals. - **R&D and formulation services** (10%) — Internal research, strain development, and vaccine formulation supporting product commercialization. - **Manufacturing services** (5%) — Production and packaging of veterinary biologics at the company's facilities in China. - Veterinary vaccine research and development - Manufacturing of livestock vaccines - Sales of veterinary vaccines - Animal health biologics for farm use ## Customers The company sells primarily to livestock-focused animal health customers in China, where vaccine purchasing is tied to herd health management and disease prevention. Its buyers are typically organizations that need consistent supply of veterinary biologics for farm and production-animal use. Demand is driven by the need to protect animal populations, reduce mortality, and support productivity in livestock operations. - **Livestock farms** (primary) — Buy veterinary vaccines for herd disease prevention and productivity protection. - **Animal health distributors** (secondary) — Purchase products for resale into veterinary and agricultural channels. - **Veterinary end users** (secondary) — Use vaccines in treatment and prevention protocols for farm animals. - Livestock operators buying vaccines to prevent disease outbreaks - Animal health distributors serving farm and veterinary channels - Agricultural customers needing repeat vaccine supply - Buyers focused on herd health and productivity protection ## Geography The business is operationally centered in Jilin, China, where the company’s principal executive office and operating base are located. Its commercial focus is China, particularly livestock vaccine demand, while the company is incorporated in the Cayman Islands and listed on Nasdaq in the United States. Geography matters because manufacturing, regulatory oversight, and end-market demand are concentrated in China even though the capital markets presence is offshore. - Operating base in Jilin Province, China - Commercial focus on livestock vaccine demand in China - Incorporated in the Cayman Islands - Listed on Nasdaq in the United States ## Strategy The company’s strategy is centered on building a veterinary vaccine platform spanning research, manufacturing, and sales. Its competitive position depends on maintaining product development capabilities and serving livestock health needs in China, where disease prevention is operationally important for producers. As a Nasdaq-listed Chinese operating company, it also depends on continued access to public capital markets and regulatory compliance. - **Strengthen veterinary vaccine pipeline** (medium-term) — New and improved vaccines support customer retention and product relevance. - **Scale manufacturing and commercial execution** (medium-term) — Integrated production and sales are necessary to meet farm and distributor demand. - **Maintain public-market compliance** (short-term) — U.S. listing status supports access to capital and investor visibility. - Expand veterinary vaccine development capability - Support livestock-focused product commercialization in China - Integrate research, manufacturing, and sales under one platform - Maintain Nasdaq listing compliance and market access ## Risks The company is exposed to demand fluctuations in livestock health markets, regulatory requirements for veterinary biologics, and execution risks in manufacturing and product quality. As a China-centered operating business with a U.S. listing, it also faces cross-border compliance, disclosure, and market volatility risks that can affect investor confidence and access to capital. - **Livestock disease and demand variability** [high] — Vaccine demand depends on animal health conditions and farm purchasing cycles. - **Manufacturing quality and product compliance** [high] — Veterinary vaccines require strict production standards and regulatory oversight. - **China concentration** [medium] — Commercial activities are focused in one country, increasing policy and market dependence. - **Nasdaq listing and trading volatility** [medium] — Share-price volatility can affect compliance status and investor perception. - Livestock disease cycles can make vaccine demand uneven - Regulatory approval and quality compliance are essential for vaccine sales - Manufacturing disruptions could affect supply and customer trust - China operating exposure adds policy and market risk - Nasdaq compliance and share-price volatility can pressure market access ## Accounting As a vaccine manufacturer, the company’s reported results are likely shaped by inventory valuation, manufacturing cost allocation, and revenue timing for product shipments. As a foreign private issuer with a China operating base, investors should also watch for judgment around related-party disclosures, contingent liabilities, and any estimates tied to plant assets or product quality matters. - **Revenue recognition for product sales** — Affects reported revenue timing and quarterly comparability - **Inventory valuation** — Affects cost of sales and gross margin - **Manufacturing overhead allocation** — Affects gross profit and inventory carrying values - **Impairment of long-lived assets** — Affects operating results and asset values - Revenue recognition depends on shipment and delivery terms for vaccine sales - Inventory valuation matters because biologics can have expiry and obsolescence risk - Manufacturing cost allocation affects gross profit on vaccine production - Fixed asset and equipment estimates can influence depreciation and impairment - Related-party and contingent liability disclosures may require judgment --- *Last updated: 2026-09-28T12:18:50.715082+00:00*